Combination therapy with etomoxir (an irreversible inhibitor of CPT1A), and orlistat (an irreversible inhibitor of lipases and fatty acid synthase) resulted in a synergistic decrease in viability of prostate cancer cell lines (LNCaP and VCaP) and patient-derived benign and prostate cancer cells. The gene discussed is CPT1A; the disease is Familial prostate cancer.